LeMaitre Vascular (NASDAQ:LMAT) Releases Earnings Results, Beats Estimates By $0.02 EPS

LeMaitre Vascular (NASDAQ:LMAT) announced its earnings results on Tuesday. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02, FiscalAI reports. The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 EPS. LeMaitre Vascular updated its FY 2026 guidance to 2.930-3.080 EPS and its Q2 2026 guidance to 0.790-0.840 EPS.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Strong Q1 and raised full‑year outlook: Q1 delivered 11% sales growth, a 72.7% gross margin and 42% EPS growth, and the company affirmed $280M full‑year revenue guidance (≈12% organic growth) while increasing margin and EPS targets.
• Artegraft is a major growth engine: Artegraft sales rose 36% in Q1 and is now the largest product—plans include international filings (Health Canada approval; launches H2‑2026; Korea/Brazil/Vietnam/India targeted in 2027), filing for longer graft packaging in H2‑2026 (first longer‑graft sales possible H2‑2027), and an FDA pre‑submission for a Quick‑Stick AV access claim.
• Operational and financial strength: Gross‑margin expansion was driven by pricing, favorable mix (higher‑margin Artegraft) and manufacturing efficiencies; cash from operations was $15M, cash/securities were $367M, and the company continues dividends and targeted commercial investment.
• RestoreFlow and regulatory timing are mixed: RestoreFlow grew 25% in Q1 with Germany distribution starting Q2 and Ireland approval expected H2 pending audit; multiple EU and Australia filings are planned but some European implants and warehousing validations have delayed near‑term ramp, leaving timing risk.

LeMaitre Vascular Trading Up 0.4%

Shares of LMAT stock traded up $0.47 on Tuesday, reaching $112.00. 225,462 shares of the company’s stock were exchanged, compared to its average volume of 173,958. LeMaitre Vascular has a 52 week low of $78.35 and a 52 week high of $118.01. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $2.56 billion, a PE ratio of 44.62, a P/E/G ratio of 3.21 and a beta of 0.60. The company’s fifty day simple moving average is $109.28 and its 200 day simple moving average is $94.17.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio is 39.84%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 55,930 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer directly owned 1,476,500 shares of the company’s stock, valued at approximately $159,181,465. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director directly owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 215,438 shares of company stock valued at $23,062,911. Insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently bought and sold shares of LMAT. EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the 2nd quarter valued at $47,000. Geneos Wealth Management Inc. raised its position in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. Quarry LP raised its position in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 529 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in LeMaitre Vascular during the 4th quarter valued at $68,000. Finally, Kemnay Advisory Services Inc. bought a new stake in LeMaitre Vascular during the 4th quarter valued at $80,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Earnings beat and year-over-year EPS growth — LMAT reported Q1 EPS of $0.68 vs. the Zacks consensus $0.66 and $0.48 a year ago, indicating margin strength and operating leverage. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised EPS guidance — LMAT set Q2 2026 EPS guidance of $0.79–$0.84 (above consensus $0.76) and FY2026 EPS guidance of $2.93–$3.08 (above consensus ~$2.90), signaling confidence in demand and near-term profitability. View Press Release
• Positive Sentiment: Dividend declared — the company announced a quarterly cash dividend of $0.25/share, which supports income-focused investors and can be viewed as a sign of cash-generative business. LeMaitre Q1 2026 Financial Results
• Positive Sentiment: Strong profitability metrics — Q1 net margin (~23.1%) and ROE (~14.7%) underline efficient operations and support the elevated EPS outlook. View Press Release
• Neutral Sentiment: Revenue roughly in line with expectations — Q1 revenue was $66.55M versus consensus ~$66.67M, effectively in line; this tempers but does not negate the EPS beat. LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Revenue guidance band roughly matches consensus — FY revenue guidance $277M–$283M brackets street estimates (~$279.5M), so upside is more EPS-driven than revenue-driven at this point. View Press Release
• Negative Sentiment: Minor revenue shortfall vs. consensus — Q1 revenue missed by about $0.12M (66.55M vs. 66.67M), which is immaterial in isolation but worth watching if the trend continues. View Press Release

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Barrington Research lifted their target price on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Roth Mkm reiterated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Wells Fargo & Company lifted their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.